November 2021 Content Release Copied

12/02/20212021 ContentContent releasePhysician, Clinical, Admin, Billing

Clinical Profile Documentation

This release updates TNM values, Stage Groupings and Template functionality for the Squamous Cell Carcinoma problem.

New documentation is required for some diagnoses. For example, Staging Type (clinical or pathological) is required for new patients to derive a Stage at diagnosis.

The new content does not affect any previous charting, which continues to be brought forward during a subsequent visit.

New

The following items are available for documentation in Problems and appear on the Charge Capture Report.

Problem ICD10 Code
History of brachytherapy Z92.3 – Personal history of irradiation
History of spinal fusion Z98.1 – Arthrodesis status
History of spinal fusion for scoliosis Z98.1 – Arthrodesis status
History of spinal fusion for kyphosis (situation) Z98.1 – Arthrodesis status

Updates

For Lung Cancer, Non-Small Cell (NSCLC) > EGFR Expression, Positive-EGFR non-sensitizing mutation is no longer available.

Bile Duct Cancer (Parent) > IDH1 Gene Mutation is now available with these options:

  • Detected
  • Not detected
  • Unknown
  • Not tested

Uterine Cancer (Parent) now includes these inference groups:

  • HER-2/neu Status
  • HER-2/neu Value-IHC
  • HER-2/neu Value-ISH

Nursing Care Procedures

In Nursing Care Procedures, Comprehensive Metabolic Profile is available and appears on the Charge Capture Report with CPT code 80053.

Lab and Panel Additions and Updates

  • Cortisol #4, ug/dL
  • Epstein-Barr nuclear Ag index IgG, AI
  • Factor VIII chromogenic nijmegen bethesda, CBU/mL
  • Ferritin
  • Final interpretation, CE
  • Final Interpretation, HPLC
  • HCT
  • Hemoglobinopathy evaluation panel, CE
  • Hemoglobinopathy evaluation panel, HPLC
  • HGB
  • Hgb A, %
  • Hgb A, CE
  • Hgb A, HPLC
  • Hgb A2
  • Hgb A2, CE
  • Hgb A2, HPLC
  • Hgb C, HPLC
  • Hgb E, HPLC
  • Hgb F
  • Hgb F, CE
  • Hgb F, HPLC
  • Hgb S, CE
  • Hgb S, HPLC
  • Hgb solubility, CE
  • Hgb variant, HPLC
  • HPLC confirmation
  • MCH
  • MCHC, g/dL
  • MCV
  • Measles, Rubeola Ab, IgM, AU
  • Parietal cell ab, elisa
  • Parietal cell ab, elisa panel
  • RBC
  • RDW
  • Rubeola Ab panel, IgM
  • SARS-CoV-2 semi-quant IgG Ab, AU/mL
  • Scleroderma Ab panel
  • Scleroderma Ab, EU
  • SLC45A2
  • Thalassemia and hemoglobinopathy comp panel
  • WBC, corrected for NRBC, x 10^3/uL

Medications

Additions

  • AGEN1777 invest IV
  • Asciminib Oral
  • ASP1570 invest Oral
  • Crizanlizumab (SEG101) invest IV
  • Enobosarm invest Oral
  • Folbic RF (B12-Levomefolate Calcium-B6 Oral 2 mg-1.13 mg-25 mg)
  • GPX-001 invest IV (Quaratusugene ozeplasmid invest)
  • LY3214996 invest Oral
  • LY3537982 invest Oral
  • Nirogacestat invest Oral
  • Ociperlimab (BGB-A1217) invest IV
  • S095029 invest IV
  • SV-BR-1-GM invest Intradermal
  • SY-5609 invest Oral
  • TPX-0131 invest Oral
  • VIP152 invest IV

Updates

Drug Change
Ferrous Sulfate Oral Form has new default
Folotyn (Pralatrexate IV) New Form: Folotyn 40 mg/2 mL (20 mg/mL) intravenous solution, NDC: 72893000501
Immun glob G(IgG)-Malt-IgA 50+ (PF) IV 10 % Removed Form 5% solution
Influenza Virus Vaccine (PF) IM Quad-Split (2yr & older) Cell Derived Renamed to Influenza Virus Vaccine (PF) IM Quad-Split (6 months & older) Cell Derived
Niraparib Oral New Form 100 mg Tablet (Also for Research)
Savolitinib invest Oral New Form 100 mg Tablet

New Sig options
Sym021 invest IV New Sig 200 mg intravenously every 2 weeks; Give 200 mg IV over 30 (+10) minutes every 2 weeks.

Regimens

Additions

  • Abemaciclib + Tamoxifen + Goserelin Q28D
  • Abemaciclib + Tamoxifen + Leuprolide Q28D
  • Abemaciclib + Tamoxifen Q28D
  • Asciminib Q30D
  • Daratumumab SQ + Carfilzomib D1,8,15 + Lenalidomide + Dexamethasone Q28D
  • Pembrolizumab + Paclitaxel + Carboplatin + Bevacizumab BIOSIMILAR Q21D (Cervical)
  • Pembrolizumab + Paclitaxel + Carboplatin Q21D (Cervical)
  • Pembrolizumab + Paclitaxel + Carboplatin Q21D (Head and Neck) (Part 1 of 2)
  • Pembrolizumab + Paclitaxel + Cisplatin + Bevacizumab BIOSIMILAR Q21D (Cervical)
  • Pemetrexed + Cisplatin + Bevacizumab BIOSIMILAR Q21D (Mesothelioma)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

  • All Problems
  • Breast Cancer
  • Graft Versus Host Disease (GVHD)
  • Immune Thrombocytopenia Purpura (ITP)
  • Leukemia, Chronic Lymphocytic (CLL)
  • Lung Cancer, Non-small Cell (NSCLC)
  • Lymphoma, Hodgkin (HL)
  • Lymphoma, Non-Hodgkin (NHL) (Parent)
  • Malignant Mesothelioma
  • Malignant Pleural Mesothelioma
  • Multiple Myeloma (MM)
  • Thyroid Cancer (Parent)
  • Waldenstrom’s Macroglobulinemia

Removal

Melphalan flufenamide + Dexamethasone Q28D

Renames

Previous Name New Name
Cabozantinib Q28D (Thyroid) Cabozantinib (Cometriq) Q28D (Medullary Thyroid)
Daratumumab SQ + Bortezomib + Melphalan PO D1-4 + Prednisone D1-4 Q42D (Part 1 of 2) Daratumumab SQ + Bortezomib + Melphalan PO + Prednisone Q42D (Part 1 of 2)
Daratumumab SQ + Bortezomib + Melphalan PO D1-4 + Prednisone D1-4 Q28D (Part 2 of 2: Daratumumab only) Daratumumab SQ + Bortezomib + Melphalan PO + Prednisone Q28D (Part 2 of 2: Daratumumab SQ only)

Research

Additions

To support Data Migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMed Generation 1 to iKnowMed Generation 2.

Updates

Updated Reference Information Updated Drug Service Order Information Updated Regimen Instruction Other Changes
USOR 18033 X
USOR 18119 X
USOR 18126 X X X Not available for ordering: USOR 18126 Part C SEA-BCMA (D1,15) + Dexamethasone (Weekly) Q28D

Available for ordering:

  • USOR 18126 Part D SEA-BCMA Intensive Dosing + Pomalidomide D1-21 + Dexamethasone (Weekly) Q28D
  • USOR Part E SEA-BCMA Intensive Dosing + Nirogacestat PO BID + Dexamethasone IV (Weekly) Q28D
USOR 18194 X
USOR 18229 X X
USOR 18283 X X
USOR 19024 X X
USOR 19036 X X X
USOR 19064 X X X Not available for ordering:

  • USOR 19064 Phase 1b Arm D Tiragolumab Q3W + Rituximab IV fb SC QW (Initial Therapy)
  • USOR 19064 Phase 1b Arm D Tiragolumab Q3W (Maintenance Therapy)

Available for ordering:

  • USOR 19064 Phase 1b Arm E Tiragolumab + Atezolizumab Q3W + Daratumumab SC (Initial Therapy)
  • USOR 19064 Phase 1b Arm E Tiragolumab + Atezolizumab Q3W + Daratumumab SC Q4W (Maintenance Therapy)
USOR 19248 X X
USOR 20171 X X X Available for ordering:

  • USOR 20171 Sintilimab + Paclitaxel + Cisplatin
  • USOR 20171 Sintilimab + Fluorouracil + Cisplatin
  • USOR 20171 Sintilimab Continuation
USOR 20178 X
USOR 20227 X X X
USOR 20270 X X X Available for ordering: USOR 20270 MRTX849 (PO; BID) Monotherapy
USOR 20278 X X
USOR 20283 X X X
USOR 20285 X X X
USOR 20344 X X X
USOR 20354 X
USOR 20396 X X
USOR 20400 X X
USOR 20408 X X
USOR 21171 X
USOR 21278 X X X

Billing: CPT and HCPCS Code Updates

Medication / Procedure CPT/HCPCS Code
COVID-19 Vaccine, mRNA, cx024414 (Moderna) (PF) IM (EUA) 91306 per 0.25 mL
Glargine-yfgn Subcutaneous Pen 100 unit/mL J1815 per 5 UNITS
Tick-Borne Encephalitis Vacc IM 90627 per 0.5 mL